CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Rhea-AI Summary

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 13, 2024, at 12:30 PM ET.

Investors can access the webcast of the fireside chat through a provided link or via the Investors section of CervoMed's website. Additionally, the company will be available for one-on-one investor meetings during the conference, offering an opportunity for more in-depth discussions about CervoMed's progress and future plans in the field of neurologic disorder treatments.

News Market Reaction – CRVO

-3.61%

-3.61% Session move

In the trading session that priced this news, CRVO declined 3.61%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA, and participate in one-on-one investor meetings.

Presentation Details
Format: Fireside Chat
Date: Tuesday, August 13, 2024
Time: 12:30 PM ET
Webcast Link: https://wsw.com/webcast/canaccord98/crvo/2485318

The webcast of the fireside chat will be accessible in the Investors section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579

FAQ

When is CervoMed (CRVO) participating in the Canaccord Genuity Growth Conference?

CervoMed (CRVO) is participating in the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, with a fireside chat scheduled for 12:30 PM ET.

Where can investors watch CervoMed's (CRVO) fireside chat at the Canaccord conference?

Investors can watch CervoMed's (CRVO) fireside chat via a webcast link provided in the press release or through the Investors section of CervoMed's website at https://www.cervomed.com/.

What type of treatments is CervoMed (CRVO) developing?

CervoMed (CRVO) is a clinical stage company focused on developing treatments for age-related neurologic disorders.

Will CervoMed (CRVO) be available for one-on-one meetings at the Canaccord conference?

Yes, CervoMed (CRVO) management will be available for one-on-one investor meetings during the Canaccord Genuity 44th Annual Growth Conference.

What is the format of CervoMed's (CRVO) presentation at the Canaccord conference?

CervoMed (CRVO) will participate in a fireside chat format presentation at the Canaccord Genuity 44th Annual Growth Conference.